What question did this study set out to answer?

This research examines the availability of screening for blood-borne viruses and PrEP in treatment facilities for stimulant use disorders.

January 25, 2026

Availability of Screening for Blood-Borne Viruses, Sexually Transmitted Infections, and HIV Pre-Exposure Prophylaxis (PrEP) at U.S. Substance Use Treatment Facilities Treating Stimulant Use Disorder.

Puntos clave

This research examines the availability of screening for blood-borne viruses and PrEP in treatment facilities for stimulant use disorders.
Survey of U.S. substance use treatment facilities
Assessment of services provided related to HIV, HCV, STI testing and PrEP
Evaluation of biospecimen collection practices
Few facilities offered comprehensive testing for HIV, HCV, and STIs
Many facilities collected biospecimens but did not provide related testing or treatment
Highlighting the need for integrated prevention and management services

Resumen

Few substance use treatment facilities provided HIV, HCV, and STI testing, PrEP, and treatment. Yet, many collect biospecimens required for testing or management of PrEP. Expansion of these services and co-location with treatment facilities are crucial strategies for prevention, early diagnosis, and timely treatment of HIV, HCV, and STI in individuals with StUD.

Me gusta

Guardar

Cite This Study

Bunting et al. (Thu,) studied this question.

synapsesocial.com/papers/6975b1eafeba4585c2d6d64f https://doi.org/https://doi.org/10.1097/qai.0000000000003833

Me gusta

Guardar